ESH Video

How I manage CAR-T Therapies and Bispecific Antibodies for my Patients

How I manage CAR-T Therapies and Bispecific Antibodies for my Patients
September 06 - September 09, 2021 - E-CONFERENCE, #ESHCART2021
Chairs : Peter Borchmann, Ulrich Jäger, Marie José Kersten

Information

How I Manage
CAR-T Therapies and Bispecific Antibodies for my Patients
#ESHCART2021

GOING VIRTUAL
NEW DATES:
September 6-9, 2021 – E-CONFERENCE


Chairpersons: Peter Borchmann (Cologne), Ulrich Jäger (Vienna), Marie José Kersten (Amsterdam)

 

About the conference:
In view of continuing COVID-19 related challenges, the ESH “How I Manage CAR-T Therapies and Bispecific Antibodies for my Patients” conference will be held as a virtual event.

REGISTRATION IS OFFERED FREE OF CHARGE as a gesture of solidarity during these difficult times.

 

About the programme:
CAR-T cells and bispecific antibodies have advanced our therapeutic armamentarium for haematological malignancies.

The programme of this ESH conference aims to provide an overview of the benefits and risks of currently available therapies for acute lymphoblastic leukaemia, lymphoma and multiple myeloma. Special focus will be placed on the advantages and disadvantages of bispecific antibodies vs. cellular therapies (including T cells, NK cells and transplant strategies). Future perspectives regarding applications in other haematological malignancies and in solid tumours will also be discussed.

The format of the meeting is based on the analysis and discussion of clinical case studies. It will adopt a problem-solving approach, addressing practical considerations and guidelines. Emphasis will be placed on open discussion, including a maximum level of interaction between faculty and registered participants.

In addition to the scientific and medical issues addressed during the conference, the questions of affordability of and access to these novel expensive treatments will be tackled by medical experts, representatives of patient organisations, economists, authorities and industry.

Learning objectives:
1. Understanding of the current landscape of bispecific antibodies
2. Understanding of the current landscape of CAR-T cells
3. Novel approaches and technologies in the field
4. Integration of novel therapies into current clinical practice
5. Future perspectives in bispecific antibody and cellular therapies in haematological malignancies and solid tumours

Programme

Click here to see the scientific programme.

The How I Manage CAR-T Therapies and Bispecific Antibodies for My Patients E-Conference 2021 has been reviewed and approved for CME-CPD accreditation by the European Board for Accreditation in Hematology (EBAH).

The EBAH has approved this educational activity for a maximum number of 10 CME-CPD credits. 

MORE INFORMATION

Abstract submission

ABSTRACTS AND CLINICAL CASES SUBMISSION IS NOW CLOSED

 

Abstracts guidelines:
– Your abstract has to be structured (eg Objectives, Methods, Results, Conclusions)
– Maximum number of words: 500
– Your abstract will be submitted to the peer review procedure.

The following file types may be uploaded: HTML document (*.htm), HTML document (*.html), JPEG image (*.jpg), GIF image (*.gif), or PNG image (*.png).

Symposia

Accommodation

Venue

CLICK HERE TO ACCESS THE E-CONFERENCE PLATFORM!

Corporate partners

With the support of*:

 

Major E-Conference Partners

*******

 

*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.

Scholarships

Workshop

Educational Grants

Registration

The registration fee for the “How I Manage CAR-T Therapies and Bispecific Antibodies for my Patients” conference is free.

Meet the Expert sessions: Registration fee: 20€
These sessions are open to E-Conference academic biologists and clinicians registrants only. A maximum of 30 seats is available in each session and pre-registration will therefore be required.

 

REGISTRATION IS NOW OPEN FOR BOTH THE E-CONFERENCE AND THE MEET THE EXPERT SESSIONS!

Register Here